Shots: The P-III development programs involves five studies assessing Bempedoic Acid (180 mg) (1,2,3,4 study) and bempedoic acid / ezetimibe combination pill vs PBO (053 study) in 4000 patients with ASCVD or HeFH Global P-III results: LDL-C lowering (18% to 31%); Reduction in hsCRP (19% to 33%); Reduction in HbA1c (0.19% to 0.31%); MACE 3/4 […]Read More
